SynthesisJournal of translational medicine2025
Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pretreatment creatinine-to-cystatin c ratio as a prognostic marker in digestive tract cancers: a meta-analysis with reconstructed individual patient data and trial sequential analysis.Frontiers in nutrition · 2026Pooled it
- Organometric and Biochemical Regularities of Transition to Aging.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2026Article
- Mediating effects of lipid metabolic and inflammatory factors on skeletal muscle mass in adults: A cross-sectional study.Medicine · 2026Article
- Protective Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026Review
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.Metabolites · 2026Review
- An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.Aging clinical and experimental research · 2026Article
- Identifying Individuals at Risk of Functional Decline Despite Preserved Muscle Mass: Insights from Appendicular Skeletal Muscle Mass and Handgrip Strength Discordance.Journal of clinical medicine · 2026Article
- Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- Age-related adiponectin resistance in human skeletal muscle dysfunction: in vivo and in vitro evidence.Journal of translational medicine · 2026Article
- From mouth to muscle: mechanistic and interventional perspectives on the tongue-coating microbiome in sarcopenia.Journal of translational medicine · 2026Review
- Creatinine/Cystatin C Ratio as a Surrogate Marker for Sarcopenia in Hepatitis-C-Associated Liver Cirrhosis After Achieving a Sustained Virologic Response.Current issues in molecular biology · 2026Article
- Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Chronic inflammation as a driving factor for sarcopenia: an update on pathophysiology and future therapeutic targets.Frontiers in pharmacology · 2026Review
- A Preliminary Predictive Panel for Pre-Frailty Based on Serum Proteomic Biomarkers: A Two-Phase Cross-Sectional Study.Clinical interventions in aging · 2026Article
- Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Modified geriatric nutritional risk index: a high-sensitivity marker with L-shaped association for sarcopenia in hospitalized older adults.Frontiers in nutrition · 2025Article
- Risk Factors, Diagnostic Challenges, and Emerging Therapeutic Strategies for ICU-Acquired Weakness: A Brief Review.Journal of multidisciplinary healthcare · 2025Review
- Identification of crosstalk genes and diagnostic biomarkers in systemic sclerosis associated sarcopenia through integrative analysis and machine learning.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBiomarkers in sarcopenia have garnered increasing interest. This study aims to systematically identify biomarkers with potential diagnostic significance for sarcopenia, as well as those exhibiting correlations with sarcopenia, particularly biomarkers reporting quantitative pooled data.
methodsThis umbrella review adhered to the PRISMA 2020 guidelines. Data sources including PubMed, the Cochrane Library, Embase, Scopus, and Web of Science were searched from the inception of data to April 7, 2025. The AMSTAR 2 tool and QUADAS-2 tool was utilized to assess the methodological quality of including studies, while the GRADE approach was used to evaluate the quality of evidence in these studies.
resultsA total of 22 studies were included. The identified biomarkers encompass inflammatory, metabolic, hormonal, amino acid-related, genetic, and other categories. The evidence quality for most biomarkers was rated as very low. The creatinine to cystatin C (Cr/CysC) ratio emerged as the most frequently utilized diagnostic biomarker, demonstrating moderate diagnostic accuracy. However, its diagnostic performance exhibited variability across different diagnostic criteria. Biomarkers associated with sarcopenia predominantly demonstrated weak or negligible inverse correlations. Inflammatory biomarkers underwent the most comprehensive investigation. Patients with sarcopenia exhibited elevated interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) levels compared to controls, with these markers showing post-intervention improvement. Some metabolic and amino acid biomarkers were found to be lower in patients with sarcopenia than in the control group.
conclusionThe Cr/CysC ratio demonstrates moderate diagnostic accuracy and represents the most frequently utilized diagnostic biomarker for sarcopenia. Inflammatory biomarkers constitute the predominant biomarkers and exhibit general elevation in sarcopenia patients. Following sarcopenia interventions, alterations in biomarker expression levels are observed, suggesting novel therapeutic applications for these biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.